Background: Oxidative stress has been suggested in the pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) with an additional burden of diabetes, hypertension and cardiovascular disease. In the present study, we investigated erythrocyte antioxidant enzymes activities in correlation to COPD severity and COPD comorbidities. Methods: One hundred twenty seven subjects with COPD and 59 healthy controls participated in this study. COPD severity was done based on the Global Initiative for Chronic Obstructive Lung Disease criteria. The erythrocytes enzyme activities of superoxide dismutase (SOD), catalase (CAT), glutathione-s-transferase (GST), glutathione peroxidase (GPx), glutathione reductase (GR) and total antioxidant status (TAS) were measured with spectrophotometric method. Results: COPD patients showed significant decrease in TAS (p > 0.05), GST (p < 0.001) and GPx (p < 0.01) activities with progression of the disease. In patients, FEV 1 was negatively correlated with SOD, GR and positively correlated with GST and GPx activities. Further, multivariate logistic regression analysis revealed GST (OR = 0.93; 95% CI = -0.10 -0.01; p < 0.01) , GPx (OR = 0.98; 95% CI = -0.03 -0.00; p < 0.05) and TAS (OR = 0.95; 95% CI = -0.08 -0.00; p < 0.05) were independently associated with FEV 1 in GOLD stage IV and GST (OR = 1.11; 95% CI = 0.04-0.18; p < 0.001) in GOLD stage II. Regression analysis confirmed a significant difference in GPx activity in COPD -type 2 diabetes (OR = 0.04; 95% CI = -6.60 -0.53; P = 0.09), and GST activity in COPD -cardiovascular disease (OR = 2.51; 95% CI = 0.00 -1.84; p < 0.05) patients when compared to patients without comorbidities. Conclusion: A significant decline in lung function may be associated with altered antioxidant enzyme activity due to the strong correlation between GST and GPx with COPD severity. Our results also indicate that erythrocytes GST and GPX activities are significantly associated with comorbidities, but only in COPD patients with type 2 diabetes and cardiovascular disease.
Identification of biomarkers for the novel therapeutics targets of Chronic obstructive pulmonary disease (COPD) is an important area of current research. In this study, the level of inflammatory cytokines was investigated and correlated these levels with erythrocytic antioxidant activities in COPD patients with smokers and without smokers and parameters of severity. Material and Methods: Plasma levels of Interleukin (IL)-6, IL-8 and IL-10 concentrations were assayed by means of Enzyme-linked Immunosorbent Assay (ELISA) and erythrocytic glutathione-stransferase (GST) and glutathione peroxidase (GPx) activities were estimated by spectrophotometric method. Results: Both IL-6 and IL-8 plasma levels showed a statistically significantly higher in COPD patients as compared to healthy controls (p<0.001; p<0.05). In contrast, the IL-10 was lower in COPD patients as compared to control group (p<0.05). FEV1 was significantly negatively correlated with plasma IL-6 (r= -0.565, p< 0.001) and IL-8 (r= -0.453, p <0.05). Plasma IL-6 was found negative association with erythrocytic GST (r= -0.018, p>0.05) and GPx activities (r= -0.080, p>0.05). Similarly IL-8 was also found negative association with GST (r= -0.260, p>0.05) and GPx activities (r= -0.268, p>0.05). Whereas, a significant positive association was observed between IL-10 and erythrocytic GST (r= 0.494, p <0.05) and GPx activities (r= 0.546, p < 0.001). Conclusion:In conclusion, Plasma levels of inflammatory cytokines IL-6 and IL-8 are related with severity of COPD and IL-10 and oxidative stress markers GST and GPx are co-dependent and strongly interrelated processes and may be used as a potential marker for the evaluation of COPD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.